Rilzabrutinib    (DrugBank: -)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
300IgG4関連疾患1

300. IgG4関連疾患 [臨床試験数:31,薬物数:33(DrugBank:16),標的遺伝子数:11,標的パスウェイ数:81
Searched query = "IgG4-related disease", "Autoimmune pancreatitis", "IgG4-related sclerosing cholangitis", "IgG4-related lacrimal gland, orbital, and salivary gland lesions", "IgG4-related kidney disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 31 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04520451
(ClinicalTrials.gov)
August 21, 202011/8/2020Open Label Two-Arm Study to Evaluate Rilzabrutinib (PRN1008) in IgG4-Related Disease PatientsAn Open Label, Two-Arm Study to Evaluate the Effect of Rilzabrutinib (PRN1008) on Safety and Disease Activity in Patients With IgG4-Related DiseaseIgG4-Related DiseaseDrug: rilzabrutinib;Drug: GlucocorticoidsPrincipia Biopharma Inc.Massachusetts General HospitalRecruiting18 YearsN/AAll25Phase 2United States